• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by new insider Doebele Robert

    2/3/25 6:29:34 PM ET
    $BOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BOLD alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Doebele Robert

    (Last) (First) (Middle)
    C/O BOUNDLESS BIO, INC.
    10955 ALEXANDRIA WAY, SUITE 100

    (Street)
    SAN DIEGO CA 92121

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    02/03/2025
    3. Issuer Name and Ticker or Trading Symbol
    Boundless Bio, Inc. [ BOLD ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Medical Officer
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    Remarks:
    Exhibit 24 - Power of Attorney.
    No securities are beneficially owned.
    /s/ Jessica Oien, Attorney- in-Fact for Robert Doebele 02/03/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $BOLD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BOLD

    DatePrice TargetRatingAnalyst
    12/13/2024Buy → Neutral
    Guggenheim
    More analyst ratings

    $BOLD
    Leadership Updates

    Live Leadership Updates

    See more
    • Boundless Bio Appoints Robert Doebele, M.D., Ph.D., as Chief Medical Officer

      SAN DIEGO, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Boundless Bio (NASDAQ:BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced that Robert ("Bob") Doebele, M.D., Ph.D., has been appointed as Chief Medical Officer. "We are excited to have Bob join Boundless at this pivotal time as we continue to advance the BBI-355 Phase 1/2 POTENTIATE trial and approach the selection of a development candidate for our Kinesin program," said Zachary Hornby, President and Chief Executive Officer of Boundless Bio. "Bob has been a driving force behind precisio

      2/3/25 10:00:00 AM ET
      $BOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BOLD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Medical Officer Doebele Robert

      4 - Boundless Bio, Inc. (0001782303) (Issuer)

      2/3/25 6:38:53 PM ET
      $BOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Doebele Robert

      3 - Boundless Bio, Inc. (0001782303) (Issuer)

      2/3/25 6:29:34 PM ET
      $BOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Scientific Officer Hassig Christian

      4 - Boundless Bio, Inc. (0001782303) (Issuer)

      1/23/25 4:05:10 PM ET
      $BOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BOLD
    SEC Filings

    See more
    • SEC Form 10-Q filed by Boundless Bio Inc.

      10-Q - Boundless Bio, Inc. (0001782303) (Filer)

      5/9/25 7:10:19 AM ET
      $BOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Boundless Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Boundless Bio, Inc. (0001782303) (Filer)

      5/9/25 7:05:23 AM ET
      $BOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Boundless Bio Inc.

      DEFA14A - Boundless Bio, Inc. (0001782303) (Filer)

      4/29/25 4:05:02 PM ET
      $BOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BOLD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Boundless Bio Reports First Quarter 2025 Financial Results and Business Highlights

      Initial proof-of-concept data from the ongoing BBI-355 Phase 1/2 POTENTIATE trial in patients with oncogene-amplified cancers anticipated in the second half of 2025 Novel Kinesin program on track for mid-2025 development candidate nomination and IND filing in the first half of 2026 $138 million cash position provides operating runway into 2027 SAN DIEGO, May 09, 2025 (GLOBE NEWSWIRE) -- Boundless Bio (NASDAQ:BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced financial results and business highlights for the fiscal quarter ended

      5/9/25 7:00:00 AM ET
      $BOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Boundless Bio to Participate in the Needham Virtual Healthcare Conference

      SAN DIEGO, April 03, 2025 (GLOBE NEWSWIRE) -- Boundless Bio (NASDAQ:BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced that Zachary Hornby, President and Chief Executive Officer, will participate in Needham's Virtual Healthcare Conference. A company presentation is scheduled for Thursday, April 10, 2025, at 1:30 p.m. ET. A live and archived webcast of the session will be accessible under "Events & Presentations" in the Investors section of Boundless Bio's website and can be accessed via this link: https://wsw.com/webcast/needham14

      4/3/25 7:00:00 AM ET
      $BOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Boundless Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

      BBI-355 Phase 1/2 POTENTIATE trial ongoing in patients with oncogene amplified cancers, with initial proof of concept data expected in the second half of 2025 Novel Kinesin program progressing toward development candidate nomination by mid-2025, with IND submission expected in the first half of 2026 With a $152 million cash position at the end of 2024, Boundless projects operating runway into 2027 SAN DIEGO, March 27, 2025 (GLOBE NEWSWIRE) -- Boundless Bio (NASDAQ:BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced financial res

      3/27/25 7:00:00 AM ET
      $BOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BOLD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Boundless Bio downgraded by Guggenheim

      Guggenheim downgraded Boundless Bio from Buy to Neutral

      12/13/24 7:26:11 AM ET
      $BOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BOLD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by Boundless Bio Inc.

      SC 13D - Boundless Bio, Inc. (0001782303) (Subject)

      10/29/24 6:32:08 PM ET
      $BOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care